UroGen Pharma Ltd. (URGN) Financials
URGN Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 193.6 million | 235.6 million |
2023-06-30 | 95.4 million | 233.8 million |
2023-03-31 | 113.0 million | 229.5 million |
2022-12-31 | 136.2 million | 225.0 million |
URGN Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -17.4 million | 2.2 million |
2023-06-30 | -20.3 million | 2.2 million |
2023-03-31 | -25.8 million | 2.3 million |
2022-12-31 | -21.8 million | 2.4 million |
URGN Net Income
No data available :(
URGN Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 147.4 million | - | 1.0 million |
2023-06-30 | 47.3 million | - | 1.2 million |
2023-03-31 | 65.1 million | 97.9 million | 1.4 million |
2022-12-31 | 100.0 million | - | 1.6 million |
URGN Shares Outstanding
URGN Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 100000 | 10.2 million | 21.8 million | - |
2023-06-30 | 15000 | 11.6 million | 22.5 million | - |
2023-03-31 | 23000 | 12.5 million | 24.5 million | - |
2022-12-31 | 13000 | 14.5 million | 21.6 million | - |
URGN Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 20.9 million | 2.4 million |
2023-06-30 | 21.1 million | 2.4 million |
2023-03-31 | 17.2 million | 2.3 million |
2022-12-31 | 18.1 million | 2.3 million |
URGN
Price: $14.26
52 week price:
Earnings Per Share: -3.55 USD
P/E Ratio: -3.83
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 20983
Ebitda: -286000Market Capitalization: 452.1 million